These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
374 related articles for article (PubMed ID: 10496984)
1. Matrix localization of tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor (TFPI-2/MSPI) involves arginine-mediated ionic interactions with heparin and dermatan sulfate: heparin accelerates the activity of TFPI-2/MSPI toward plasmin. Liu Y; Stack SM; Lakka SS; Khan AJ; Woodley DT; Rao JS; Rao CN Arch Biochem Biophys; 1999 Oct; 370(1):112-8. PubMed ID: 10496984 [TBL] [Abstract][Full Text] [Related]
2. Regulation of ProMMP-1 and ProMMP-3 activation by tissue factor pathway inhibitor-2/matrix-associated serine protease inhibitor. Rao CN; Mohanam S; Puppala A; Rao JS Biochem Biophys Res Commun; 1999 Feb; 255(1):94-8. PubMed ID: 10082661 [TBL] [Abstract][Full Text] [Related]
3. Prokaryotic expression, purification, and reconstitution of biological activities (Antiprotease, antitumor, and heparin-binding) for tissue factor pathway inhibitor-2. Rao CN; Reddy P; Reeder DJ; Liu Y; Stack SM; Kisiel W; Woodley DT Biochem Biophys Res Commun; 2000 Oct; 276(3):1286-94. PubMed ID: 11027624 [TBL] [Abstract][Full Text] [Related]
4. Inhibitory properties of a novel human Kunitz-type protease inhibitor homologous to tissue factor pathway inhibitor. Petersen LC; Sprecher CA; Foster DC; Blumberg H; Hamamoto T; Kisiel W Biochemistry; 1996 Jan; 35(1):266-72. PubMed ID: 8555184 [TBL] [Abstract][Full Text] [Related]
5. HT-1080 fibrosarcoma cell matrix degradation and invasion are inhibited by the matrix-associated serine protease inhibitor TFPI-2/33 kDa MSPI. Rao CN; Cook B; Liu Y; Chilukuri K; Stack MS; Foster DC; Kisiel W; Woodley DT Int J Cancer; 1998 May; 76(5):749-56. PubMed ID: 9610735 [TBL] [Abstract][Full Text] [Related]
6. Expression of serine proteinase inhibitor PP5/TFPI-2/MSPI decreases the invasive potential of human choriocarcinoma cells in vitro and in vivo. Jin M; Udagawa K; Miyagi E; Nakazawa T; Hirahara F; Yasumitsu H; Miyazaki K; Nagashima Y; Aoki I; Miyagi Y Gynecol Oncol; 2001 Nov; 83(2):325-33. PubMed ID: 11606093 [TBL] [Abstract][Full Text] [Related]
7. Extracellular matrix-associated serine protease inhibitors (Mr 33,000, 31,000, and 27,000) are single-gene products with differential glycosylation: cDNA cloning of the 33-kDa inhibitor reveals its identity to tissue factor pathway inhibitor-2. Rao CN; Reddy P; Liu Y; O'Toole E; Reeder D; Foster DC; Kisiel W; Woodley DT Arch Biochem Biophys; 1996 Nov; 335(1):82-92. PubMed ID: 8914837 [TBL] [Abstract][Full Text] [Related]
8. Inhibition of serine proteinases plasmin, trypsin, subtilisin A, cathepsin G, and elastase by LEKTI: a kinetic analysis. Mitsudo K; Jayakumar A; Henderson Y; Frederick MJ; Kang Y; Wang M; El-Naggar AK; Clayman GL Biochemistry; 2003 Apr; 42(13):3874-81. PubMed ID: 12667078 [TBL] [Abstract][Full Text] [Related]
9. Inhibitory properties of separate recombinant Kunitz-type-protease-inhibitor domains from tissue-factor-pathway inhibitor. Petersen LC; Bjørn SE; Olsen OH; Nordfang O; Norris F; Norris K Eur J Biochem; 1996 Jan; 235(1-2):310-6. PubMed ID: 8631347 [TBL] [Abstract][Full Text] [Related]
10. Inhibition of neutrophil cathepsin G by oxidized mucus proteinase inhibitor. Effect of heparin. Boudier C; Cadène M; Bieth JG Biochemistry; 1999 Jun; 38(26):8451-7. PubMed ID: 10387091 [TBL] [Abstract][Full Text] [Related]
11. Activation of heparin cofactor II by heparin and dermatan sulfate. Tollefsen DM Nouv Rev Fr Hematol (1978); 1984; 26(4):233-7. PubMed ID: 6548014 [TBL] [Abstract][Full Text] [Related]
13. The role of tissue factor pathway inhibitor-2 in cancer biology. Sierko E; Wojtukiewicz MZ; Kisiel W Semin Thromb Hemost; 2007 Oct; 33(7):653-9. PubMed ID: 18000791 [TBL] [Abstract][Full Text] [Related]
15. Quantification and characterization of human endothelial cell-derived tissue factor pathway inhibitor-2. Iino M; Foster DC; Kisiel W Arterioscler Thromb Vasc Biol; 1998 Jan; 18(1):40-6. PubMed ID: 9445254 [TBL] [Abstract][Full Text] [Related]
16. Tissue factor pathway inhibitor; its structure, function and clinical significance. Kato H Pol J Pharmacol; 1996; 48(1):67-72. PubMed ID: 9112630 [TBL] [Abstract][Full Text] [Related]
17. Substitution of arginine for Leu444 in the reactive site of heparin cofactor II enhances the rate of thrombin inhibition. Derechin VM; Blinder MA; Tollefsen DM J Biol Chem; 1990 Apr; 265(10):5623-8. PubMed ID: 2138609 [TBL] [Abstract][Full Text] [Related]